Chao Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/133207/publications.pdf

Version: 2024-02-01

1163117 1474206 9 366 8 9 citations h-index g-index papers 9 9 9 755 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 491-504.	4.2	1
2	Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell Death and Disease, 2021, 12, 396.	6.3	12
3	Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica, 2020, 105, 1630-1640.	3.5	46
4	Targeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells. Life Sciences, 2019, 227, 153-165.	4.3	19
5	Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient. Academic Radiology, 2018, 25, 904-914.	2.5	31
6	Metformin induces autophagy and GO/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. Journal of Experimental and Clinical Cancer Research, 2018, 37, 63.	8.6	181
7	Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leukemia and Lymphoma, 2017, 58, 428-437.	1.3	18
8	Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF- \hat{l}^2B signaling. BMC Cancer, 2015, 15, 248.	2.6	21
9	Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1060-1070.	4.9	37